Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer

Katsuyuki Hotta, I. Sekine, K. Suzuki, H. Kondo, Hisao Asamura, M. Sumi, N. Yamamoto, H. Kunitoh, Y. Ohe, T. Tamura, T. Kodama, N. Saijo, R. Tsuchiya

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The standard treatment for patients with locoregional recurrence of non-small cell lung cancer (NSCLC) after complete resection has not been established. The aim of this study was to evaluate clinicopathologic characteristics, type of locoregional recurrence, pattern of subsequent failure, and survival after the recurrence. Methods: Of 743 patients undergoing pulmonary resection for NSCLC in the National Cancer Center Hospital between 1990 and 1995, we retrospectively reviewed the medical charts of the 43 patients (5.8%) found to have locoregional recurrence without distant metastasis or pleural or pericardial involvement. Results: The median time to locoregional recurrence was 13.6 months (range: 1.6-85.8 months). The most frequent site of recurrence was the mediastinal nodes in 21 of 43 patients (49%). 33 patients (77%) received further treatment for the recurrence: thoracic irradiation in 26, surgery in two, systemic chemotherapy in two, and a combination of the above in 3 patients. Subsequent distant failure was detected in 26 (68%) of the 38 patients assessable for the analysis of failure pattern: lung in 11, brain in 6, bone in 5, and others in 13. The median interval from the recurrence to distant failure was 8.4 months (range: 1.7-56.4 months). The median survival time after diagnosis of the locoregional recurrence was 10.5 months (range: 0-74.0 months). A multivariate analysis showed that local therapy for the locoregional recurrence had no significant impact on postrecurrent survival or distant failure-free survival. Conclusions: Many patients with postoperative locoregional recurrence developed distant metastases early after the first recurrence. Systemic chemotherapy in addition to local therapy may be of benefit in this population.

Original languageEnglish
Pages (from-to)283-287
Number of pages5
JournalThoracic and Cardiovascular Surgeon
Volume51
Issue number5
DOIs
Publication statusPublished - 2003 Oct
Externally publishedYes

Fingerprint

Treatment Failure
Non-Small Cell Lung Carcinoma
Recurrence
Survival
Neoplasm Metastasis
Cancer Care Facilities
Drug Therapy
Lung
Therapeutics
Thorax
Multivariate Analysis
Bone and Bones

Keywords

  • Distant failure
  • Local therapy
  • Non-small cell lung cancer
  • Postoperative locoregional recurrence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer. / Hotta, Katsuyuki; Sekine, I.; Suzuki, K.; Kondo, H.; Asamura, Hisao; Sumi, M.; Yamamoto, N.; Kunitoh, H.; Ohe, Y.; Tamura, T.; Kodama, T.; Saijo, N.; Tsuchiya, R.

In: Thoracic and Cardiovascular Surgeon, Vol. 51, No. 5, 10.2003, p. 283-287.

Research output: Contribution to journalArticle

Hotta, K, Sekine, I, Suzuki, K, Kondo, H, Asamura, H, Sumi, M, Yamamoto, N, Kunitoh, H, Ohe, Y, Tamura, T, Kodama, T, Saijo, N & Tsuchiya, R 2003, 'Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer', Thoracic and Cardiovascular Surgeon, vol. 51, no. 5, pp. 283-287. https://doi.org/10.1055/s-2003-43089
Hotta, Katsuyuki ; Sekine, I. ; Suzuki, K. ; Kondo, H. ; Asamura, Hisao ; Sumi, M. ; Yamamoto, N. ; Kunitoh, H. ; Ohe, Y. ; Tamura, T. ; Kodama, T. ; Saijo, N. ; Tsuchiya, R. / Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer. In: Thoracic and Cardiovascular Surgeon. 2003 ; Vol. 51, No. 5. pp. 283-287.
@article{799bd85701634a3a9be1b684656a0514,
title = "Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer",
abstract = "Background: The standard treatment for patients with locoregional recurrence of non-small cell lung cancer (NSCLC) after complete resection has not been established. The aim of this study was to evaluate clinicopathologic characteristics, type of locoregional recurrence, pattern of subsequent failure, and survival after the recurrence. Methods: Of 743 patients undergoing pulmonary resection for NSCLC in the National Cancer Center Hospital between 1990 and 1995, we retrospectively reviewed the medical charts of the 43 patients (5.8{\%}) found to have locoregional recurrence without distant metastasis or pleural or pericardial involvement. Results: The median time to locoregional recurrence was 13.6 months (range: 1.6-85.8 months). The most frequent site of recurrence was the mediastinal nodes in 21 of 43 patients (49{\%}). 33 patients (77{\%}) received further treatment for the recurrence: thoracic irradiation in 26, surgery in two, systemic chemotherapy in two, and a combination of the above in 3 patients. Subsequent distant failure was detected in 26 (68{\%}) of the 38 patients assessable for the analysis of failure pattern: lung in 11, brain in 6, bone in 5, and others in 13. The median interval from the recurrence to distant failure was 8.4 months (range: 1.7-56.4 months). The median survival time after diagnosis of the locoregional recurrence was 10.5 months (range: 0-74.0 months). A multivariate analysis showed that local therapy for the locoregional recurrence had no significant impact on postrecurrent survival or distant failure-free survival. Conclusions: Many patients with postoperative locoregional recurrence developed distant metastases early after the first recurrence. Systemic chemotherapy in addition to local therapy may be of benefit in this population.",
keywords = "Distant failure, Local therapy, Non-small cell lung cancer, Postoperative locoregional recurrence",
author = "Katsuyuki Hotta and I. Sekine and K. Suzuki and H. Kondo and Hisao Asamura and M. Sumi and N. Yamamoto and H. Kunitoh and Y. Ohe and T. Tamura and T. Kodama and N. Saijo and R. Tsuchiya",
year = "2003",
month = "10",
doi = "10.1055/s-2003-43089",
language = "English",
volume = "51",
pages = "283--287",
journal = "Thoracic and Cardiovascular Surgeon",
issn = "0171-6425",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - Distant Failure after Treatment of Postoperative Locoregional Recurrence of Non-Small Cell Lung Cancer

AU - Hotta, Katsuyuki

AU - Sekine, I.

AU - Suzuki, K.

AU - Kondo, H.

AU - Asamura, Hisao

AU - Sumi, M.

AU - Yamamoto, N.

AU - Kunitoh, H.

AU - Ohe, Y.

AU - Tamura, T.

AU - Kodama, T.

AU - Saijo, N.

AU - Tsuchiya, R.

PY - 2003/10

Y1 - 2003/10

N2 - Background: The standard treatment for patients with locoregional recurrence of non-small cell lung cancer (NSCLC) after complete resection has not been established. The aim of this study was to evaluate clinicopathologic characteristics, type of locoregional recurrence, pattern of subsequent failure, and survival after the recurrence. Methods: Of 743 patients undergoing pulmonary resection for NSCLC in the National Cancer Center Hospital between 1990 and 1995, we retrospectively reviewed the medical charts of the 43 patients (5.8%) found to have locoregional recurrence without distant metastasis or pleural or pericardial involvement. Results: The median time to locoregional recurrence was 13.6 months (range: 1.6-85.8 months). The most frequent site of recurrence was the mediastinal nodes in 21 of 43 patients (49%). 33 patients (77%) received further treatment for the recurrence: thoracic irradiation in 26, surgery in two, systemic chemotherapy in two, and a combination of the above in 3 patients. Subsequent distant failure was detected in 26 (68%) of the 38 patients assessable for the analysis of failure pattern: lung in 11, brain in 6, bone in 5, and others in 13. The median interval from the recurrence to distant failure was 8.4 months (range: 1.7-56.4 months). The median survival time after diagnosis of the locoregional recurrence was 10.5 months (range: 0-74.0 months). A multivariate analysis showed that local therapy for the locoregional recurrence had no significant impact on postrecurrent survival or distant failure-free survival. Conclusions: Many patients with postoperative locoregional recurrence developed distant metastases early after the first recurrence. Systemic chemotherapy in addition to local therapy may be of benefit in this population.

AB - Background: The standard treatment for patients with locoregional recurrence of non-small cell lung cancer (NSCLC) after complete resection has not been established. The aim of this study was to evaluate clinicopathologic characteristics, type of locoregional recurrence, pattern of subsequent failure, and survival after the recurrence. Methods: Of 743 patients undergoing pulmonary resection for NSCLC in the National Cancer Center Hospital between 1990 and 1995, we retrospectively reviewed the medical charts of the 43 patients (5.8%) found to have locoregional recurrence without distant metastasis or pleural or pericardial involvement. Results: The median time to locoregional recurrence was 13.6 months (range: 1.6-85.8 months). The most frequent site of recurrence was the mediastinal nodes in 21 of 43 patients (49%). 33 patients (77%) received further treatment for the recurrence: thoracic irradiation in 26, surgery in two, systemic chemotherapy in two, and a combination of the above in 3 patients. Subsequent distant failure was detected in 26 (68%) of the 38 patients assessable for the analysis of failure pattern: lung in 11, brain in 6, bone in 5, and others in 13. The median interval from the recurrence to distant failure was 8.4 months (range: 1.7-56.4 months). The median survival time after diagnosis of the locoregional recurrence was 10.5 months (range: 0-74.0 months). A multivariate analysis showed that local therapy for the locoregional recurrence had no significant impact on postrecurrent survival or distant failure-free survival. Conclusions: Many patients with postoperative locoregional recurrence developed distant metastases early after the first recurrence. Systemic chemotherapy in addition to local therapy may be of benefit in this population.

KW - Distant failure

KW - Local therapy

KW - Non-small cell lung cancer

KW - Postoperative locoregional recurrence

UR - http://www.scopus.com/inward/record.url?scp=10744228971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228971&partnerID=8YFLogxK

U2 - 10.1055/s-2003-43089

DO - 10.1055/s-2003-43089

M3 - Article

C2 - 14571346

AN - SCOPUS:10744228971

VL - 51

SP - 283

EP - 287

JO - Thoracic and Cardiovascular Surgeon

JF - Thoracic and Cardiovascular Surgeon

SN - 0171-6425

IS - 5

ER -